Supernus Announces New Qelbree® Data Showing Improvement in

Topline results from Phase IV study demonstrate Qelbree is safe and well-tolerated, and significantly improved efficacy outcomes when added to a stimulant...

Related Keywords

United States ,Alice Sofield ,Peter Vozzo ,Jacka Khattar ,Las Vegas ,Ann Childress ,Andrewj Cutler ,Timothyc Dec ,Jonathan Rubin ,Psych Congress ,Nasdaq ,Neuroscience Education Institute ,Securities Exchange ,Supernus Pharmaceuticals ,Research Development ,Supernus Pharmaceuticals Inc ,Exchange Commission ,Chief Medical Officer ,Senior Vice President ,Concomitant Use ,Behavioral Medicine ,Open Label Extension Trial ,Symptom Rating Scale ,Global Executive Composite ,Clinical Associate Professor ,Medical University ,Neuroscience Education ,Prescribing Information ,Boxed Warning ,Private Securities Litigation Reform Act ,Securities Exchange Act ,Nasdaq Supn ,Nc ,